OKYO Pharma Limited Grant of options -- Director dealings (7629W)
21 August 2020 - 4:00PM
UK Regulatory
TIDMOKYO
RNS Number : 7629W
OKYO Pharma Limited
21 August 2020
OKYO Pharma Limited
("OKYO" or the "Company")
Grant of options - Director dealings
London, 21 August, 2020 - OKYO Pharma Limited (LSE: OKYO)
("OKYO" or the "Company"), the life sciences and biotechnology
company, focused on the discovery and development of novel
molecules to treat inflammatory dry eye diseases and chronic pain,
is pleased to announce, announces that the board of directors of
the Company (the "Board" or "Directors"), with Mr Brancaccio
absenting himself on grounds of interest, has awarded the following
options on 20 August 2020.
(a) Keeren Shah
Ms Shah has been awarded options to acquire 300,000 ordinary
shares in the capital of the Company. The options are exercisable
at a price of 15.5 pence per share (being the mid-market closing
price of the Company's shares traded on the LSE on 20 August 2020).
The options will vest in equal tranches over four years beginning
on the date of grant.
(b) John Brancaccio
Mr Brancaccio has been awarded options to acquire 450,000
ordinary shares in the capital of the Company. The options are
exercisable at a price of 15.5 pence per share (being the
mid-market closing price of the Company's shares traded on the LSE
on 20 August 2020). The options will vest in equal tranches over
four years beginning on the date of grant, subject to attainment of
the criteria set out below. Mr Brancaccio has no existing interests
in ordinary shares in the capital of the Company.
The options would vest over 4 years and in tranches so that each
tranche would vest on a standalone or aggregated basis should the
total shareholder return in each financial year be equal to, or
exceed, 10%, as reported in the annual report and accounts for the
Company for the relevant financial year and the first measurement
period being in respect of the financial year ended 31 March 2021,
with the decision as whether vesting had occurred to be taken on
the business day following the publication of the relevant
financial results.
The criteria for vesting are designed to align with shareholder
interests and only to vest if shareholders benefit from enhanced
value creation. The criteria of total shareholder return has been
used as a performance benchmark on the basis that it is a figure
which is independently audited annually.
This information set out below is provided in accordance with
Article 19(3) of EU Regulation 596/2014.
1. Details of PDMR / person closely associated
a) Name (i) Keeren Shah
(ii) John Brancaccio
------------------ --------------------------------------------
2. Reason for the notification
----------------------------------------------------------------
a) Position (i) Finance Director
/ status (ii) Non-Executive
------------------ --------------------------------------------
b) Initial Initial notification
notification
/amendment
------------------ --------------------------------------------
3. Details of the issuer
----------------------------------------------------------------
a) Name OKYO Pharma Limited
------------------ --------------------------------------------
b) LEI 213800VVN5CB56Y15A05
------------------ --------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------
a) Description Ordinary Shares of no par value
of the
financial
instrument
------------------ --------------------------------------------
b) Identification ISIN for OKYO Pharma Limited: GG00BD3FV870
code of
the Financial
Instrument
------------------ --------------------------------------------
c) Nature Grant of options
of the
transaction
------------------ --------------------------------------------
d) Price(s) Price Volume
and volume(s) (i) 15.5p (i) 300,000
(ii) 15.5p (ii) 450,000
------------------ --------------------------------------------
f) Date of 20 August 2020
the transaction
------------------ --------------------------------------------
g) Place of XLON
the transaction
------------------ --------------------------------------------
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379
Optiva Securities Limited
Investors: Robert Emmet + 44 (0)20 3981 4173
Dave Gentry RedChip Companies
dave@redchip.com Inc. +1 407-491-4498
For further information, please visit the Company's website at
www.okyopharma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKBLFLBVLXBBK
(END) Dow Jones Newswires
August 21, 2020 02:00 ET (06:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024